ESMO expert Markus Joerger gives his views on the JAVELIN Renal 101 study pitting the combination of avelumab and axitinib against sunitinib in the first-line advanced RCC setting.

View more on Medicine Matters oncology: [ Ссылка ]

More from ESMO 2018: [ Ссылка ]

*Originally published on Medicine Matters oncology on October 30, 2018*

свернуть